BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — whose sequence is derived from a protein found in human gastric juice. It is one of the most widely studied peptides in preclinical literature and one of the most frequently misrepresented in commercial marketing. This guide covers what the molecule actually is, what the published research does and does not show, how the compound is characterised analytically, and how to handle it in a laboratory setting.
SOMA Research supplies BPC-157 for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.
What BPC-157 is
BPC-157 is a partial sequence of Body Protection Compound, a protein isolated from gastric juice. The fifteen-residue fragment is produced synthetically rather than extracted. Its published identifiers are:
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
- CAS number: 137525-51-0
- Molecular formula: C62H98N16O22
- Molecular weight: approximately 1,419.5 g/mol
- Length: 15 amino acids
- Appearance: white to off-white lyophilised powder
The sequence is unusually proline-rich — four of fifteen residues are proline. Proline introduces conformational rigidity into a peptide backbone, which is one structural reason the molecule resists enzymatic degradation better than many short peptides of comparable length. This stability in aqueous and acidic conditions is a recurring observation in the published characterisation work and is relevant to how the compound behaves in in vitro assay buffers.
Acetate salt versus free base
Most research-grade BPC-157 is supplied as the acetate salt. This matters for two practical reasons. First, the stated mass of a vial includes the counter-ion, so the peptide content by weight is lower than the nominal figure — typically in the region of 80–90% depending on the acetate content, which a full Certificate of Analysis will state. Second, acetate salts are hygroscopic, so vials should be brought to room temperature before opening to avoid condensing atmospheric moisture into the powder.
If your calculations depend on exact molarity rather than nominal mass, read the peptide-content figure on the CoA rather than assuming the label weight is pure peptide. Our guide on how to read a Certificate of Analysis covers where that figure appears and how it relates to the HPLC purity number, which is a different measurement.
What the published research examines
The BPC-157 literature is almost entirely preclinical — cell culture and rodent models. The principal mechanistic threads are:
- Angiogenic signalling. Several studies report effects on vascular endothelial growth factor receptor 2 (VEGFR2) signalling and downstream endothelial pathways in cultured cells.
- Nitric oxide pathway interaction. A substantial body of rodent work examines the compound in the context of NO synthesis, frequently using L-NAME and L-arginine as pharmacological probes to dissect the pathway.
- Growth factor expression. Reported changes in expression of growth factor receptors in tissue models.
- Gastrointestinal models. Given its origin in gastric juice, a large fraction of the literature uses gastrointestinal injury models in rodents.
Two caveats belong next to that list, and researchers evaluating the compound should hold both. The published work is overwhelmingly from a small number of research groups, which limits independent replication. And there are no completed, published, peer-reviewed human clinical trials establishing safety or efficacy for any indication. Claims that circulate commercially about human outcomes are not supported by that evidence base. This is a compound for laboratory investigation, not a therapeutic.
BPC-157 and TB-500
These two are frequently paired in catalogues, including ours, and they are not variants of one another.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric juice protein fragment | Thymosin beta-4 fragment |
| Length | 15 amino acids | 7 amino acids |
| Molecular weight | ~1,419.5 g/mol | ~889 g/mol |
| Primary mechanistic focus in literature | Angiogenic and NO pathway signalling | Actin sequestration and cell migration |
The mechanistic distinction is the useful one: TB-500 derives from a protein whose best-characterised function is binding G-actin, which places its literature in the cytoskeletal and cell-motility domain. BPC-157’s literature sits in the vascular and signalling domain. A researcher comparing them is comparing two different pathways, not two doses of one idea. SOMA lists both separately and as a blend.
Analytical characterisation
Two orthogonal measurements are needed to characterise a peptide batch, and a CoA that reports only one is incomplete:
- HPLC (reversed-phase) answers how pure. It separates the target peptide from truncated sequences, deletion products and synthesis-related impurities, and reports the target as a percentage of total peak area.
- Mass spectrometry answers what it is. For BPC-157 the observed mass should correspond to approximately 1,419.5 g/mol. A correct mass with a poor purity figure means the right molecule in a dirty preparation; a clean HPLC trace with the wrong mass means a pure preparation of something else.
Every SOMA lot is tested by third-party laboratories using both methods, and the measured figures for each lot are published on our CoA library.
Handling and storage
- Lyophilised powder: store at -20°C, protected from light. Stable for 24 months or more under those conditions.
- Before opening: allow the vial to reach room temperature, to prevent moisture condensing into the hygroscopic powder.
- Reconstituted stock: store at 2–8°C and use within approximately 30 days.
- Freeze-thaw: aliquot after reconstitution. Repeated freeze-thaw cycles are a common and avoidable cause of degradation.
- Reconstitution: direct the solvent down the vial wall rather than onto the powder, and swirl rather than shake.
The full procedure, including the concentration arithmetic and the difference between bacteriostatic and sterile water, is in our reconstitution guide.
Why synthesis impurities matter for a peptide this short
A fifteen-residue peptide is built one residue at a time on a solid-phase resin. Each coupling step is efficient but not perfect, and the failures accumulate in a predictable way: a chain that misses a coupling becomes a deletion sequence one residue shorter than the target. With fifteen couplings, even a 99% step yield leaves roughly 14% of the material as something other than the full-length product before purification.
This is why the HPLC figure on a CoA is not a formality. The impurities in a peptide preparation are mostly close structural relatives of the target — same chemistry, similar retention, and invisible to any test that only confirms the mass of the main component. They are the reason a reversed-phase trace is the measurement that distinguishes batches, and the reason a supplier who publishes only a mass spectrum is telling you half the story.
A related point specific to BPC-157: the sequence contains two adjacent aspartic acid residues (Asp-Asp at positions 10 and 11). Aspartyl residues are a known site for aspartimide formation during synthesis and for isomerisation on storage in solution. A well-resolved HPLC method will separate those related species; a short or poorly resolved gradient may not. If a trace looks implausibly clean for the sequence, the method is worth reading as carefully as the result.
What to check before using a batch
- Does the CoA match the vial? The lot number on the document and the lot number on the label should be the same string. A generic CoA that is not lot-specific characterises a different batch than the one in your hand.
- Are both tests present? HPLC purity and mass-spectrometry identity. One without the other leaves a gap.
- Is the test date after the manufacture date? A CoA predating the lot it describes is not describing that lot.
- Is peptide content stated separately from purity? These are different numbers and conflating them will bias any molarity calculation.
- Is the testing laboratory named? An unnamed lab cannot be checked.
The same checklist, with worked examples of each field, is in the Certificate of Analysis guide.
Related guides
Research use only
Research-grade BPC-157 is supplied for laboratory use by qualified researchers and institutions. It is not manufactured to pharmaceutical standards, has not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that the compound is safe or effective for any purpose.
